[
    [
        {
            "time": "2018-10-12",
            "original_text": "[看好评级]医药生物行业2018年三季报业绩前瞻：医药需求刚性 预计增长保持稳健",
            "features": {
                "keywords": [
                    "医药生物",
                    "三季报",
                    "业绩前瞻",
                    "需求刚性",
                    "增长稳健"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[看好评级]医药生物行业2018年三季报业绩前瞻：医药需求刚性 预计增长保持稳健",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-10-12",
            "original_text": "[推荐评级]医药行业周报：17种抗癌药纳入国家医保 研发驱动型企业长期受益",
            "features": {
                "keywords": [
                    "医药行业",
                    "抗癌药",
                    "国家医保",
                    "研发驱动",
                    "长期受益"
                ],
                "sentiment_score": 0.85,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[推荐评级]医药行业周报：17种抗癌药纳入国家医保 研发驱动型企业长期受益",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-10-12",
            "original_text": "【申万宏源医药闫天一团队】20181012周观点：医药需求刚性，预计增长保持稳健——医药生物行业2018年三季报业绩前瞻",
            "features": {
                "keywords": [
                    "申万宏源",
                    "医药需求",
                    "刚性",
                    "增长稳健",
                    "三季报"
                ],
                "sentiment_score": 0.88,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【申万宏源医药闫天一团队】20181012周观点：医药需求刚性，预计增长保持稳健——医药生物行业2018年三季报业绩前瞻",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 4,
                "Headline_Structure": 8,
                "Source_Recency": 3
            }
        }
    ]
]